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Abstract
Background:  Progestins as respiratory stimulants in chronic obstructive pulmonary disease
(COPD) have been investigated in males and during wakefulness. However, sleep and gender may
influence therapeutic responses. We investigated the effects of a 2-week medroxyprogesterone
acetate (MPA) therapy on sleep and nocturnal breathing in postmenopausal women.
Methods: A single-blind placebo-controlled trial was performed in 15 postmenopausal women
with moderate to severe COPD. A 12-week trial included 2-week treatment periods with placebo
and MPA (60 mg/d/14 days). All patients underwent a polysomnography with monitoring of SaO2
and transcutaneous PCO2 (tcCO2) at baseline, with placebo, with medroxyprogesterone acetate
(MPA 60 mg/d/14 days), and three and six weeks after cessation of MPA.
Results: Thirteen patients completed the trial. At baseline, the average ± SD of SaO2 mean was
90.6 ± 3.2 % and the median of SaO2 nadir 84.8 % (interquartile range, IQR 6.1). MPA improved
them by 1.7 ± 1.6 %-units (95 % confidence interval (CI) 0.56, 2.8) and by 3.9 %-units (IQR 4.9; 95%
CI 0.24, 10.2), respectively. The average of tcCO2 median was 6.0 ± 0.9 kPa and decreased with
MPA by 0.9 ± 0.5 kPa (95% CI -1.3, -0.54). MPA improved SaO2 nadir and tcCO2 median also during
REM sleep. Three weeks after cessation of MPA, the SaO2 mean remained 1.4 ± 1.8 %-units higher
than at baseline, the difference being not significant (95% CI -0.03, 2.8). SaO2 nadir was 2.7 %-units
(IQR 4.9; 95% CI 0.06, 18.7) higher than at baseline. Increases in SaO2 mean and SaO2 nadir during
sleep with MPA were inversely associated with baseline SaO2 mean (r = -0.70, p = 0.032) and
baseline SaO2 nadir (r = -0.77, p = 0.008), respectively. Treatment response in SaO2 mean, SaO2
nadir and tcCO2 levels did not associate with pack-years smoked, age, BMI, spirometric results or
sleep variables.
Conclusion: MPA-induced respiratory improvement in postmenopausal women seems to be
consistent and prolonged. The improvement was greater in patients with lower baseline SaO2
values. Long-term studies in females are warranted.
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Background
Chronic obstructive pulmonary disease (COPD), consist-
ing of variable degrees of pulmonary emphysema and
chronic obstructive bronchitis, has a male predominance.
However, the prevalence of COPD is steadily increasing
among women [1] as a consequence of increased rates of
cigarette smoking. Women may be more sensitive to the
deleterious effects of smoking than men[2]. Mortality due
to COPD is increasing among women,[3] which may not
merely reflect the increasing overall prevalence, but also
the increase of the most severe forms of COPD. Therefore,
novel therapeutic options are needed to cope with COPD.
Decreased production of progestins after menopause may
result in lack of natural respiratory stimulation and pre-
dispose women to respiratory insufficiency. Therefore,
progestin replacement therapy could effectively improve
ventilation and oxygenation during sleep.
Hypoxemia and hypercapnia during sleep herald respira-
tory insufficiency. Many studies have investigated effects
of progestins on breathing in awake subjects but few stud-
ies have evaluated the effect of progestin treatment on
nocturnal breathing in patients with respiratory insuffi-
ciency, mostly due to COPD [4-9]. In light of the previous
observations, the effect of progestin therapy on breathing
may be weaker during sleep[5]. A key issue is that the
aforementioned studies have recruited almost entirely
men. However, effects of progestin therapy may be gen-
der-dependent. We have previously reported of sustained
progestin-induced improvement in awake blood gases of
postmenopausal women with respiratory insuffi-
ciency[10]. We hypothesised that the beneficial effects of
medroxyprogesterone acetate (MPA) would also be dem-
onstrated as improved SaO2 and tcCO2 during sleep. We
therefore wanted to evaluate the degree and duration of
MPA effect on sleep and nocturnal breathing in postmen-
opausal women with chronic respiratory disease and
show that MPA effectively improves SaO2 and tcCO2 dur-
ing sleep in postmenopausal women with moderate to
severe COPD.
Methods
Patient selection
15 consecutive postmenopausal women with COPD ful-
filling the inclusion criteria and willing to volunteer were
recruited for the trial by using our hospital data base. The
inclusion criteria were forced expiratory volume in one
second (FEV1) less than 65 % of predicted value[11]. The
criteria for postmenopausal status were age over 50 yr,
time since last menstruation at least 12 months, and
serum concentrations of follicle-stimulating hormone
(FSH) > 30 IU/l. All patients were receiving optimal ther-
apy and had been in a stable clinical condition for at least
a month prior the study.
The exclusion criteria included malignancies, heart dis-
eases (except cor pulmonale), insulin dependent diabetes
mellitus, previous thromboembolic events, obstructive
sleep apnea syndrome, untreated hypothyroidism, any
other major diseases, current smoking, long-term oxygen
therapy and use of systemic postmenopausal hormone
therapy. Patients were on their regular medication that
was found optimal by their pulmonologist. Medication
varied from patient to patient and included both short-
and long-acting inhaled beta-agonists, anticholinergics
and inhaled corticosteroids. No changes in medication
were allowed throughout the study period. Medication
likely to influence sleep or vigilance such as benzodi-
azepines, psychostimulants, melatonin or antidepressants
were not allowed. Vaginal estrogen therapy was allowed
since vaginal application does not affect serum estradiol
levels.
All patients gave their written informed consents. The
study protocol was approved by the Joint Commission on
Ethics of Turku University and Turku University Central
Hospital.
Study design
The 12-week study followed a placebo-controlled single-
blind design (Fig. 1) and included five nights at 3-week
intervals in sleep laboratory. Seven days after the baseline
measurements, all patients started with placebo treatment
for 14 days. After a 7-day interval, MPA treatment for 14
days was started. Patients were then followed-up for six
weeks after cessation of MPA. We found it important that
the placebo night data would be obtained before the
patients had received MPA. Based on our earlier observa-
tions,[10,12,13] MPA-induced effects are measurable for
weeks after cessation of progestin therapy. To exclude the
carry-over effect, more than a 6-week washout period
would be needed between the treatments. Knowing that
acute exacerbations are frequent in patients with moder-
ate to severe COPD, the longer duration of the study
would increase the drop-out rate markedly. Therefore, the
placebo and MPA studies were not done in a random
sequence.
30 mg of oral MPA (Lutopolar®, Orion Pharma, Espoo,
Finland) or placebo tablets provided by the same pharma-
ceutical company were administered twice in the evening,
at 9 PM and 11 PM. Peak serum concentrations are
reached within one to three hours followed by a sharp
decline thereafter[14]. MPA was divided in two doses
given two hours apart to minimize the variation in MPA
levels during night. Compliance was assessed by tablet
counts, patient interviews and measurements of serum
MPA concentrations. The overnight polysomnography
was registered five times at 3-week intervals: at baseline,
after 14 days on placebo, after 14 days on MPA, and afterRespiratory Research 2005, 6:28 http://respiratory-research.com/content/6/1/28
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3- and 6-week washout periods. Sleep studies were per-
formed at a university sleep laboratory, where the techni-
cian was present during the recording. In the evening,
patients were weighed, and at each visit blood pressure
was measured by the same researcher, using the ausculta-
tory method in seated subjects. Every morning after sleep
study patients completed a structured questionnaire with
14 separate items concerning their subjective sleep quality
during the past night[15]. Questions were related to initi-
ation and maintenance of sleep (for example, perceptions
of sleep latency, frequency of awakenings), events during
sleep (for example, restlessness), sleep-related daytime
symptoms (for example, naps during the preceding day),
and issues possibly disturbing sleep (for example, dysp-
noea, sweating). Flow-volume spirometry (Vitalograph
Compact II, Vitalograph Ltd, Buckingham, England) was
assessed in the morning after the sleep study.
An overnight polysomnography included electroencepha-
logram, electro-oculogram, and chin electromyogram.
Arterial oxyhemoglobin saturation (SaO2) was measured
with pulse oximeter using a finger probe (Ohmeda Biox
3700 Pulse Oximeter, BOC Health Care, U.S.A.). The
response time setting for the pulse oximeter was 6 sec-
onds. Partial pressure of carbon dioxide (tcCO2) was
measured transcutaneously (TINA® Transcutaneous pO2/
pCO2  Monitoring System, Radiometer, Copenhagen,
Denmark). After cleansing the skin with alcohol the skin
sensor was placed on the upper part of the chest paraster-
nally and heated up to 43.5°C, at which temperature the
Study design Figure 1
Study design. Both placebo (PL) and medroxyprogesterone acetate (MPA) periods lasted for 14 days. Arrows indicate the 
timing of sleep studies, dashed line the timing and duration of the placebo period and solid line thetiming and duration of the 
MPA period.Respiratory Research 2005, 6:28 http://respiratory-research.com/content/6/1/28
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sensor could remain attached continuously for 8 hours.
Body movements were monitored with a static-charge-
sensitive bed[16,17]. Quantitative movement analysis
and SaO2 analyses were performed with custom made
analysis modules (UniPlot®, Unesta, Turku, Finland).
Nasal pressure was recorded with nasal prongs connected
to a presser transducer. The nasal pressure signal was ana-
lysed with Sullivan Autoset device (Sullivan Autoset®, Res-
Care Limited, Sydney, Australia) used in a diagnostic
mode and with a separate inspiratory flow shape analysis
software described earlier[18]. Biosignals were recorded
and stored with sampling frequency of 250 Hz per chan-
nel and with y-resolution of 12 bytes (UniPlot®, Unesta,
Turku, Finland). The episodes of arterial oxyhemoglobin
desaturation of 4 %-units or more per hour (ODI4) were
calculated with Uniplot®  software (UniPlot®, Unesta,
Turku, Finland). EtCO2 and tcCO2 signals were recorded
with a sampling frequency of 100 Hz throughout the
night by Embla® system (Embla®, Flaga, Reykjavik, Ice-
land). The SaO2  and tcCO2  data were analyzed on a
breath-by-breath basis. Each breath was assigned with the
sleep stage during which it occurred. This was achieved
using an MS-Excel macro, which combined the informa-
tion from the two files according to time tags. The maxi-
mum inspiratory slope during the initial part of
inspiration was determined on a breath-by-breath basis
from the nasal pressure signal and used as an index of res-
piratory drive as previously described[19,20].
Sleep stages and arousals were scored according to stand-
ard criteria[21,22] and expressed as percentage of total
sleep time. Sleep efficiency was defined as percentage
sleep during the sleep period time.
Statistical analyses
The overall comparisons between repeated measurements
were performed with either nonparametric Friedman's
test or parametric analysis of variance (ANOVA) for
repeated measurements. In nonparametric case Wilcoxon
signed ranks test and in parametric case F-test were used.
In repeated measurements, Bonferroni correction was
used for p-values. All comparisons were made to baseline
measurements. Comparisons between the first and the
second sessions tested the placebo effect, between the first
and the third sessions the immediate effect of MPA,
between the first and the fourth and the first and the fifth
the sustained effect of MPA. Correlation analyses were
performed with Pearson correlation method and p-values
were corrected with Bonferroni method. In all tests, p <
0.05 was considered significant. Statistical computing was
performed with SAS statistical package (version 8.01, SAS
Institute, Cary, NC).
Results
13 out of 15 patients completed the trial. Two subjects dis-
continued due to acute exacerbation of their COPD after
the second visit. None of the subjects had clinical symp-
toms of OSAS. Mean (± SD) ODI4 was 1.4 ± 1.9/h at base-
line and did not change during the trial. Laboratory
assessments were within inclusion criteria in all but one
patient. She had low serum FSH (S-FSH 25 IU/L). How-
ever, she was considered postmenopausal based on her
age (71 years) and her serum concentration of estradiol
(36 pmol/L, postmenopausal reference range < 140 pmol/
L), and included in the trial. According to tablet count, all
patients were compliant and after the two-week treatment
MPA was detectable in all patients confirming their com-
pliance. After a three-week washout MPA was under the
detection limit in three patients and near the detection
limit in the rest, and after a six-week washout undetecta-
ble in all patients. No correlations were found between
serum MPA levels and SaO2 or tcCO2. We were not able to
analyse the EtCO2 data due to insufficient plateaus in
EtCO2 signals.
Baseline characteristics of patients are presented in Tables
1 and 2. Weight, dyspnea or other symptom scores, blood
pressure, or spirometric values did not differ during the
trial. None of the patients had a history of snoring, wit-
nessed apnea or excessive sleepiness. Patients reported
that they slept as usual and woke up several times during
night. They had no specific complaints disturbing their
sleep. Subjective sleep quality and total time in bed did
not differ throughout the trial. MPA did not induce any
Table 1: Characteristics of patients at baseline.
N = 15 Mean SD Range
Age (yr) 67.5 6.0 56 – 76
BMI (kg/m2) 26.9 4.9 15.4 – 35.2
Smoking (pack-year) 8.8 13.9 0 – 50
FEV1(L) 0.76 0.3 0.44 – 1.80
FEV1(%) 34 12.4 15 – 63
FVC (L) 1.25 0.5 0.77 – 1.69
FVC (%) 44 16.2 26 – 72
FEV% 61 13.7 48 – 77
Arterial pH 7.38 0.05 7.25 – 7.45
PaCO2(kPa) 6.0 1.1 5.5 – 9.9 74.2
PaO2 (kPa) 9.0 1.2 5.6 – 12.6
Systolic BP (mmHg) 154 21.8 120 – 190
Diastolic BP (mmHg) 87 14.1 60 – 118
BMI = body mass index, FEV1 = forced expiratory volume in one 
second, FVC = forced vital capacity, FEV% = 100 × (FEV1/FVC), 
PaCO2 = partial tension of arterial carbon dioxide, PaO2 = partial 
tension of arterial oxygen.Respiratory Research 2005, 6:28 http://respiratory-research.com/content/6/1/28
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alterations in objectively measured polygraphic sleep
parameters. Three women had withdrawal bleeding after
cessation of MPA therapy, one of them was on vaginal
estrogen therapy. The other two women had benign
endometrial findings underlying their withdrawal
bleeding.
No changes in respiratory or sleep parameters were found
during placebo period compared to baseline. We analyzed
the effects of MPA during sleep and separately according
to sleep stages. Both SaO2 mean and SaO2 nadir improved
in 11 out of 13 (85 %) patients during sleep. tcCO2
median improved with MPA in 12 out of the 13 women
(92 %). At baseline, the SaO2 mean averaged 90.6 ± 3.2 %
(95% Bonferroni corrected confidence interval (CI) 88.3,
92.9; Fig. 2). The average increase with MPA was 1.7 ± 1.6
%-units (95% CI 0.56, 2.84; p = 0.044). The median of
SaO2 nadir was 84.8 % (interquartile range, IQR 6.1; 95%
CI 66.5, 87.3) at baseline and improved by 3.9 %-units
(IQR 4.8; 95% CI 0.24, 10.2; p = 0.024; Fig. 2.) with MPA.
At baseline, the mean of tcCO2 median was 6.0 ± 0.9 kPa
(CI 95% 5.4, 6.6) and decreased by 0.9 ± 0.5 kPa with
MPA (CI 95 % -1.3, -0.5; p = 0.004; Fig. 2.) There was a
borderline increase in the median of maximum
inspiratory slope from 10.4 (IQR 4.7; 95% CI 7.0, 23.7)
U/50-1 at baseline to 18.9 (IQR 22.4; CI 95% 11.0, 62.9)
U/50-1 with MPA (p = 0.068).
Three weeks after cessation of MPA, SaO2 mean and SaO2
nadir sustained to be higher in 11 out of 13 patients dur-
ing sleep, when compared to baseline. The average of
SaO2 mean was 1.4 ± 1.8 (95% corrected CI -0.03, 2.8) %-
units higher, the difference being statistically not signifi-
cant after Bonferroni corrections (p = 0.028 prior to the
correction; p = 0.112 after Bonferroni correction, n = 11,
Fig. 2). The median SaO2 nadir was 2.7 %-units (IQR 4.9;
95% CI 0.06, 18.7) higher than at baseline (p = 0.032). Six
weeks after MPA administration SaO2 nadir or SaO2 mean
did not differ from baseline. Within three weeks after ces-
sation of MPA, tcCO2 median was lower compared to
baseline in 6 out of 13 patients but the mean of tcCO2
median had returned to baseline (Fig. 2).
The pattern of MPA effect on SaO2 nadir (Fig. 3), SaO2
mean (Fig. 4), and tcCO2 median (Fig. 5) was quite simi-
lar during stages S1, S2, slow wave sleep (SWS; stages S3
and S4) and rapid eye movement (REM) sleep. Impor-
tantly, MPA had a marked effect also during REM sleep
(Fig. 3, 4, 5). The median of maximum inspiratory slope
increased from 10.7 (IQR 4.6; 95% CI 6.5, 30.0) U/50-1
at baseline to 16.8 (IQR 30.7) U/50-1 with MPA (95% CI
11.8, 59.0; p = 0.042) during stage 4 sleep.
Increases in SaO2 mean and SaO2 nadir during sleep with
MPA were inversely associated with baseline SaO2 mean (r
= -0.70, p = 0.032) and baseline SaO2 nadir (r = -0.77, p =
0.008), respectively. Decrease in tcCO2 with MPA did not
correlate neither with baseline SaO2 nor tcCO2 levels.
Treatment response in SaO2 mean, SaO2 nadir and tcCO2
levels did not associate with pack-years smoked, age, BMI,
baseline spirometric results or sleep variables.
Discussion
The present data show that MPA effectively improves
SaO2 and tcCO2 during sleep in postmenopausal women
with moderate to severe COPD. The improvement seems
to be greater in patients with lower baseline SaO2. None
of the previous studies has systemically used MPA to stim-
ulate nocturnal breathing in female patients with COPD.
The effect seems to be more consistent in female than in
male patients with COPD[5]. The pattern of MPA effect
was quite similar over the array of sleep stages and MPA
had beneficial effects also during REM sleep. Even when
administered at higher doses than in ordinary gynecologic
indications, MPA was also well tolerated.
We used the maximum inspiratory slope as an index of
respiratory drive. Although we have used the inspiratory
slope index previously in patients with partial upper air-
way obstruction during sleep[19,20], it can also be used in
populations without partial upper airway obstruction
such as in patients with COPD. It is a non-invasive index
affected also by upper airway dynamics. The different
contributing factors are not calculated separately but the
index reflects a "total output" during the initial part of
inspiration. Since this index is insufficiently validated, the
results should be considered suggestive and interpreted
with caution. At baseline, the maximum slope in this
group of women with moderate to severe COPD was com-
patible with that of healthy postmenopausal women[20].
Table 2: Objective sleep quality at baseline, N = 15.
Sleep Recording Data at 
Baseline
TST 4 h 34 min ± 1 h 13 min
Sleep efficiency 66 ± 18 % of sleep period time
EEG arousals 2.6 ± 3.3 / h of sleep
Movement arousals 9.7 ± 7.1 / h of sleep
Latency to S2 sleep 41 ± 41 min
Stage S1 sleep 87 ± 60 min (34 ± 24 %)
Stage S2 sleep 81 ± 48 min (29 ± 15 %)
SWS 73 ± 39 min (26 ± 10 %)
REM sleep 34 ± 31 min (11 ± 10 %)
Percentages indicate proportion of the total sleep time (TST) unless 
otherwise indicated. Data presented as mean ± SD. REM = rapid eye 
movements, SWS = slow wave sleep (sleep stages 3 and 4), TST = 
total sleep time.Respiratory Research 2005, 6:28 http://respiratory-research.com/content/6/1/28
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Changes of SaO2 nadir, SaO2 mean, and tcCO2 median during sleep with MPA and after a 3- and a 6-week follow-up Figure 2
Changes of SaO2 nadir, SaO2 mean, and tcCO2 median during sleep with MPA and after a 3- and a 6-week fol-
low-up. Changes are absolute percentage values. MPA = medroxyprogesterone acetate, SaO2 = arterial oxygen saturation, 
tcCO2 = transcutaneous partial carbon dioxide tension. The error bars of SaO2 mean and tcCO2 median represent standard 
deviation and those of SaO2 nadir represent interquartile ranges. P-values are corrected with Bonferroni method. ** = p < 
0.01, * = p < 0.05.Respiratory Research 2005, 6:28 http://respiratory-research.com/content/6/1/28
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It was also compatible with the maximum inspiratory
slope in postmenopausal women with partial upper air-
way obstruction during sleep using MPA[20]. Although
the maximum inspiratory slope was already at baseline
within normal postmenopausal range, MPA almost dou-
bled the slope. This finding is in line with the thinking
that the baseline respiratory drive in women with COPD
is not decreased compared to healthy postmenopausal
women and that exogenous respiratory stimulation
increases the respiratory drive above the physiological
postmenopausal level in these patients.
Our results differ to some extent from the previous studies
by other groups. First, in our female patients, the respira-
tory improvement seems to be more consistent than in
the previous studies recruiting almost entirely male
patients. SaO2 mean and SaO2 nadir increased in 11 out of
13 (85 %) and tcCO2 median decreased with MPA in 12
out of the 13 women (92 %) during sleep. Previously, in
17 men and two women with COPD, MPA (60 mg/d/1
month) improved SaO2 during sleep only in five out of 19
patients[5]. The authors did not report, whether both of
the studied women were among the responders. In six
non-obese men with COPD, MPA (100 mg/d/15 days)
decreased the number of hypoxemic episodes during
sleep[6].
Second, the CO2 levels were not monitored during sleep
in most previous studies. In the present study, lowering of
tcCO2 was short-lived paralleling to the pattern observed
Changes of SaO2 nadir during different sleep stages with MPA and after a 3- and a 6-week follow-up Figure 3
Changes of SaO2 nadir during different sleep stages with MPA and after a 3- and a 6-week follow-up. Changes are 
absolute percentage values. MPA = medroxyprogesterone acetate, SaO2 = arterial oxygen saturation. The error bars of SaO2 
nadir represent interquartile ranges. P-values are corrected with Bonferroni method. ** = p < 0.01.Respiratory Research 2005, 6:28 http://respiratory-research.com/content/6/1/28
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in base excess previously in awake patients[10]. Our find-
ings are consistent with those observed in 17 hypercapnic
stable patients with COPD, where nocturnal end-tidal
CO2  decreased by 0.9 kPa with MPA (60 mg/d/2
weeks)[9]. Our results are also in line with observations in
awake healthy males, where MPA increased alveolar ven-
tilation and slopes of hypercapnic and hypoxic ventilatory
responses[23]. tcCO2 reflects the metabolic tissue per-
formance[24] and the slow changes of the absolute partial
arterial carbon dioxide tension (PaCO2)[25]. According to
Sanders and co-workers,[26] tcCO2 does not consistently
and accurately reflect PaCO2 and may even overestimate
it[27]. However, tcCO2 measurements show the direction
and rough magnitude of the changes in CO2 levels. There
is no indication that PaCO2 would be superior to tcCO2 to
monitor the metabolic condition at the tissue level. We
used tcCO2 as a surrogate for PaCO2 in order to avoid
invasive measurements. Nothing suggests so far that
transcutaneous CO2  measurements would affect sleep
quality. However, we think that neither end tidal CO2 nor
tcCO2 represents directly PaCO2 but that all the three
measurements reflect different phenomena. Frequent
nocturnal sampling of arterial blood gases would increase
our understanding about the blood-tissue interactions of
acid-base balance and needs to be considered in future
studies.
Third, MPA effectively improved oxygenation and tcCO2
also during REM sleep. In a previous study in patients
with COPD, MPA (60 mg/d/4 weeks) decreased PaCO2
Changes of SaO2 mean during different sleep stages with MPA and after a 3- and a 6-week follow-up Figure 4
Changes of SaO2 mean during different sleep stages with MPA and after a 3- and a 6-week follow-up. Changes 
are absolute percentage values. MPA = medroxyprogesterone acetate, SaO2 = arterial oxygen saturation. The error bars of 
SaO2 mean represent standard deviation. P-values are corrected with Bonferroni method.Respiratory Research 2005, 6:28 http://respiratory-research.com/content/6/1/28
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and increased PaO2 only during non-REM sleep and had a
similar trend during REM sleep[28].
Fourth, the possible after-effects of MPA on breathing
were usually not evaluated in previous studies. The respi-
ratory effects of a two-week treatment with MPA of 60 mg
daily subsided within 14 days in healthy male sub-
jects[29]. In patients with COPD, Wagenaar and
coworkers did not observe any after-effects on respiration
one month after cessation of combined therapy with MPA
and acetazolamide (gender distribution in study popula-
tion not reported)[9]. Prolonged improvement of day-
time PaCO2  in women with chronic respiratory
insufficiency[10] and of nocturnal end tidal CO2 in post-
menopausal women with partial upper airway
obstruction during sleep[13] has been a consistent find-
ing in our previous studies. The present study showed a
sustained improvement in SaO2 nadir.
The obviously more consistent and prolonged effect of
MPA on respiration in our female patients compared to
that in male patients in previous studies may be explained
by differences in study populations or MPA dosage
regimen. We recruited only women. Although both estro-
gen and progesterone concentrations in postmenopausal
women are at the same level than in men, the effects of
progestin therapy may remain gender-specific. Sex ster-
oids influence neuromodulatory serotonergic neu-
Changes of the mean of tcCO2 median during different sleep stages with MPA and after a 3- and a 6-week follow-up Figure 5
Changes of the mean of tcCO2 median during different sleep stages with MPA and after a 3- and a 6-week fol-
low-up. Changes are absolute percentage values. MPA = medroxyprogesterone acetate, tcCO2 = transcutaneous partial car-
bon dioxide tension. The error bars of tcCO2 represent standard deviation. P-values are corrected with Bonferroni method. ** 
= p < 0.01, * = p < 0.05.Respiratory Research 2005, 6:28 http://respiratory-research.com/content/6/1/28
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rons,[30] which are critically involved in the neural
control of breathing[31,32]. Serotonin has an excitatory
effect on upper airway and phrenic motoneurons [33-37].
Animal studies demonstrate a greater serotonin activity in
female than in male brain[30,38]. The number and distri-
bution of progesterone receptors may differ between gen-
ders because androgens down-regulate progesterone and
estrogen receptors without affecting progesterone or estra-
diol concentrations[39]. Estradiol increases the number
of progesterone receptors[40]. In ovariectomized rats,
MPA did not stimulate breathing until progesterone
receptors were upregulated with estrogen[41]. MPA-
derived metabolites with intrinsic estrogenic activity[42]
may upregulate progesterone receptors more effectively in
women than in men.
The duration of respiratory effects of MPA may differ
between healthy individuals and those with respiratory
impairment like COPD or sleep-disordered breathing.
The persistent effect of MPA may be due to modification
of peripheral or central chemoreceptor action or central
processing of the carotid body neural output[43]. MPA
may reset the respiratory center for a new response level.
The homeostatic regulatory mechanisms aim to maintain
the normal function in the body. Therefore, the new
response threshold of the respiratory center is maintained
longer in subjects with respiratory impairment than in
healthy subjects. The elimination of MPA might be slower
in diseased patients than in healthy individuals. However,
this is unlikely to explain the persistent respiratory effect
in our patients, since MPA concentrations were below or
near the detection limit within three weeks after cessation
of MPA.
Our relatively high MPA dose was chosen to ensure effec-
tive respiratory stimulation during night. Therefore, we
also administered the whole dose of MPA in the evening.
MPA reaches its peak serum concentration within one to
three hours and the concentrations decline quite rapidly
thereafter[14]. 60 mg per day is the most commonly used
dose in studies where respiration is stimulated by MPA.
However, it is usually divided in three doses administered
at 8-hour intervals. MPA-induced persistent respiratory
effects may be attributed to the alteration in endocrino-
logical environment, or pharmacodynamics of MPA. MPA
alters hormone levels, and their recuperation may take for
weeks at least in women[12]. In an animal model, the
clearance of MPA-related substances is slow in the lung,
skeletal muscle and brain tissues[44]. Although MPA has
a stronger progestational activity than progesterone, it
does not have greater effects on breathing than progester-
one[29]. This observation may indicate that the metabo-
lites of MPA cause the respiratory effects rather than MPA
itself.
MPA did not have any effect on subjective or objective
sleep quality in our patients. In postmenopausal women,
MPA (5 mg/d) combined with estrogen had no effect on
objective sleep parameters but improved subjective sleep
quality[45]. According to previous studies, MPA has
induced no consistent effects on sleep[5,6,13,28,46-50].
The arousal indexes were low. Part of this could be due to
true suppression of arousals by hypoxemia and sleep dep-
rivation. On the other hand, many of the arousals initi-
ated a whole epoch of wakefulness, resulting in
technically low arousal index, compared to healthy eld-
erly people or patients with COPD.
Because our patients spent most of the time in light sleep,
arousals easily resulted in awakenings and thereby in
lower arousal index than previously reported in healthy
elderly people[51] or in patients with COPD[52,53]. Our
patients were also hypoxemic and sleep deprived with an
average total sleep time less than 5 hours. Both hypox-
emia[54,55] and sleep deprivation [56,57] increase
arousal threshold resulting in lower arousal index.
The single blind study design is a limitation of our study.
We refrained from using a cross-over design knowing that
acute exacerbations frequently occur in patients with
moderate to severe COPD, and therefore the longer dura-
tion of the study would increase the drop-out rate mark-
edly. Although a cross-over setting was not feasible, a
parallel group design would have strengthened the data
and needs to be considered for future trials. Another lim-
itation is the small study population. Although the
number of patients recruited was based on our previous
trials[10,13], the results of the current study indicated that
a greater number of subjects would have strengthened
especially the tcCO2 results. However, we are confident
that correction of these shortcomings would only have
been strengthened, not undone our findings.
Conclusion
Taken together, MPA 60 mg daily for 14 days improved
breathing during sleep in postmenopausal women with
COPD. Some of the effects persisted for weeks after cessa-
tion of MPA. Our patients were not homogenous in terms
of baseline arterial blood gases and nocturnal SaO2. Some
of them had values likely to threaten their life expectancy,
others had minor impairments. Patients with more severe
hypoxemia seemed to improve more than those with
milder respiratory impairment. Our results warrant fur-
ther studies into the long-term efficacy and feasibility of
MPA administered either on a cyclical or on a continuous
basis to support breathing during sleep in postmenopau-
sal women with clinically significant hypoxia or
hypercapnia.Respiratory Research 2005, 6:28 http://respiratory-research.com/content/6/1/28
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